|
Angiotensin II Blockade Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Angiotensin II Blockade conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Angiotensin II Blockade Clinical research trials and Angiotensin II Blockade healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Angiotensin II Blockade. Angiotensin II Blockade Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Angiotensin II Blockade clinical trial. Human subjects often obtain the finest healthcare possible for their Angiotensin II Blockade condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Angiotensin II Blockade  Angiotensin II Blockade
Angiotensin II Blockade
For Condition: chronic allograft nephropathy,Post Transplant Proteinuria
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical interstitial compartment of the kidney where most of the scarring occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney diseases.
Details:
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age > 18 years. - Recipients of a first or a second renal transplant alone or in combination with a pancreas transplantation. - Informed consent - Adequate baseline biopsy; at least 10 cortical projection fields. Exclusion Criteria: - Age < 18 years. - Serum creatinine 2.5mg/dL. - Persistent hyperkalemia; potassium > 5.4 mEq/L. - Known hypersensitivity to losartan or iodine allergy. - Documented renal artery stenosis by duplex ultrasonography. - Recipients of grafts from an HLA-identical sibling. - Recipients whose primary renal disease is primary hyperoxaluria,dense-deposit disease, focal segmental glomerulosclerosis or hemolytic uremic syndrome. - Women of childbearing age who wish to become pregnant and/or are unwilling to use contraceptive measures or who are pregnant. - Recipients requiring ACE inhibitors or AII blockers for a cardiovascular indication (e.g. systolic dysfunction). - Recipients who are > 55 years old and had a history of cardiovascular disease (coronary artery disease, stroke or peripheral vascular disease).
Total Enrollment: 136
Location and Contact Information:
University of Minnesota *Recruiting*
Minneapolis, Minnesota, 55455
United States
Recruiting Hassan Ibrahim 612-624-9930
Hennepin County Medical Center *Recruiting*
Minneapolis, Minnesota, 55415
United States
Recruiting John Slikensen 612-347-5871
Additional Information:
Study ID Numbers: ANGIOB;
Study Start Date: December 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067990
Other Post Transplant Proteinuria Studies:
1. Antibody and Delayed Cyclosporine versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
2. Prevention of Kidney Transplant Rejection
3. Angiotensin II Blockade
Related Studies:
Other Post Transplant Proteinuria Clinical Trials
Other Minnesota Clinical Trials
Other Minneapolis Clinical Trials
Angiotensin II Blockade
|
|
|
|
|
|
|
|
